Wells Fargo’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Wells Fargo’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-5,296	Closed	-$210K	–	6675
2016 Q3	$210K	Buy	+5,296	New	+$59.1K	﹤0.01%	4461
2016 Q2	–	Sell	-270	Closed	-$2K	–	6574
2016 Q1	$2K	Buy	270 +247	+1,074%	+$1.86K	﹤0.01%	6068
2015 Q4	$0	Buy	23 +12	+109%	+$125	﹤0.01%	6604
2015 Q3	$0	Sell	11 -110	-91%	-$1.54K	﹤0.01%	6662
2015 Q2	$2K	Buy	121 +25	+26%	+$366	﹤0.01%	6194
2015 Q1	$1K	Buy	96 +16	+20%	+$172	﹤0.01%	6110
2014 Q4	$1K	Buy	80 +1	+1%	+$9	﹤0.01%	6143
2014 Q3	$1K	Sell	79 -43	-35%	-$849	﹤0.01%	6128
2014 Q2	$7K	Sell	122 -719	-85%	-$43.7K	﹤0.01%	5750
2014 Q1	$95K	Buy	+841	New	+$59K	﹤0.01%	4677

Wells Fargo's TBRA Position: Q4 2016 in Review

Wells Fargo sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 5,296 shares — an estimated $210K sold.

Wells Fargo first reported a position in TBRA in Q1 2014 and held it in 10 quarters. The position peaked at $210K in Q3 2016. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

Wells Fargo reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Wells Fargo sold 5,296 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $210K.
Wells Fargo first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2014 and held it in 10 quarters.
Wells Fargo's Tobira Therapeutics, Inc. Common Stock position peaked at $210K in Q3 2016.
0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.